Silence Therapeutics PLC News - SLN

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short...

Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short...

Silence Therapeutics to Participate in September Investment Conferences

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short...

Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera

Designation provides potential for expedited drug development path Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under...

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Table of Contents Filed Pursuant to Rule 424(b)(5)Registration No. 333-260265 PROSPECTUS SUPPLEMENT...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Silence Therapeutics Announces Pricing of Underwritten Offering

Silence Therapeutics plc (Nasdaq: SLN) (“Silence”), a leader in the discovery, development and delivery of novel short interfering ribonucleic...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Statement of Beneficial Ownership (sc 13d)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of...

Silence Therapeutics to Present at Jefferies Healthcare Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short...

H.C. Wainwright Thinks Silence Therapeutics’ Stock is Going to Recover

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report), with a...

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Monksdream 4 months ago

SLN over $20

👍️0

Monksdream 5 months ago

SLN new 52 week hi

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Silence Therapeutics PLC (SLN)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

SLN News

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference

Silence Therapeutics to Participate in September Investment Conferences

Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Silence Therapeutics Announces Pricing of Underwritten Offering

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Statement of Beneficial Ownership (sc 13d)

Silence Therapeutics to Present at Jefferies Healthcare Conference

H.C. Wainwright Thinks Silence Therapeutics’ Stock is Going to Recover

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

SLN Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Silence Therapeutics PLC (SLN) News

Silence Therapeutics PLC (SLN)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

SLN News

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference

Silence Therapeutics to Participate in September Investment Conferences

Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Silence Therapeutics Announces Pricing of Underwritten Offering

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Statement of Beneficial Ownership (sc 13d)

Silence Therapeutics to Present at Jefferies Healthcare Conference

H.C. Wainwright Thinks Silence Therapeutics’ Stock is Going to Recover

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

SLN Discussion

Your Recent History